Homepage Archives - Page 2 of 3 - Geneseeq Technology Inc. | A Precision Oncology Company

May 19, 2022

Geneseeq collaborates on another minimal residual disease study in chemoradiotherapy-treated inoperable localized non-small cell lung cancer patients.

April 5, 2022

Geneseeq Presents 9 Posters at AACR 2022

January 4, 2022

Geneseeq’s cancer early detection study series DECIPHER yield another publication in HEPATOLOGY to explore the performance of cfDNA fragmentomics in liver cancer

November 11, 2021

Geneseeq Forms Lung Cancer Strategic Partnerships with Takeda and AstraZeneca on the Same Day

November 8, 2021

Geneseeq collaborates on research identifying predictive biomarkers for guiding personalized adjuvant treatment in resected EGFR-positive non-small cell lung cancer

October 13, 2021

Geneseeq and Zai Lab Announce Strategic Collaboration to Advance Cancer Drug R&D

September 15, 2021

Geneseeq Presents 10 studies on MRD, early cancer detection, cancer diagnosis and cancer biology research at EMSO 2021

August 31, 2021

Geneseeq Study Evaluates ctDNA MRD to Predict Response to Therapy and Assess Prognosis in Locally Advanced Rectal Cancer

June 24, 2021

Geneseeq works with HUTCHMED and AstraZeneca in MET inhibitor approval for lung cancer patients in China

June 17, 2021

Geneseeq Joins Integrated DNA Technologies (IDT) Align Program